

Validation data for Anti-CoV2RBD-cas-hIgG1 & Anti-CoV2RBD-imd-hIgG1

<https://www.invivogen.com/sars2-spike-regn-mab>

For research use only

Version 21J22-NJ

Anti-CoV2RBD-cas-hIgG1 and Anti-CoV2RBD-imd-hIgG1 are recombinant monoclonal antibodies (mAbs) featuring the variable region of the REGN10933 (aka Casirivimab) and REGN10987 (aka Imdevimab) human mAbs, respectively. They both feature a human IgG1 constant region and they specifically target the SARS-CoV-2 Spike receptor-binding domain (RBD). The binding capacity of InvivoGen's Anti-CoV2RBD-cas-hIgG1 (**Figure 1A**) and Anti-CoV2RBD-imd-hIgG1 (**Figure 1B**) to a set of Spike variants has been validated using a Lucia luciferase-based ELISA.

Binding of Anti-CoV2RBD-cas-hIgG1 and Anti-CoV2RBD-imd-hIgG1 to RBD variants




Figure 1: Anti-human or Anti-murine IgG F(ab')₂ fragment (2 µg/ml) was coated on an ELISA plate overnight. Anti-CoV2RBD-cas-hIgG1 or -mIgG2a (**A**), Anti-CoV2RBD-imd-hIgG1 or -mIgG2a (**B**) along with RBD-Lucia proteins (original and V3; 1 µg/ml) were added and incubated for 2 hours at room temperature. After washing (3x times), binding affinity was assessed by measuring the activity of Lucia luciferase in the supernatant using QUANTI-Luc™. Data are shown as a fold change over no antibody.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Asia: +852 3-622-34-80

E-mail: info@invivogen.com